Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case Posted on May 2, 2016May 2, 2016 by christian@orphandrugsindustry.com Link to article Share this:TwitterFacebookLinkedInPrintRedditTumblrEmailPinterestPocket